ES2989065T3 - Precursores del inhibidor de la PDE4 bioactivados de la microbiota intestinal - Google Patents

Precursores del inhibidor de la PDE4 bioactivados de la microbiota intestinal Download PDF

Info

Publication number
ES2989065T3
ES2989065T3 ES21813912T ES21813912T ES2989065T3 ES 2989065 T3 ES2989065 T3 ES 2989065T3 ES 21813912 T ES21813912 T ES 21813912T ES 21813912 T ES21813912 T ES 21813912T ES 2989065 T3 ES2989065 T3 ES 2989065T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
acetyl
pyridin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21813912T
Other languages
English (en)
Spanish (es)
Inventor
Bernard Côte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Giiant Pharma Inc
Original Assignee
Giiant Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giiant Pharma Inc filed Critical Giiant Pharma Inc
Application granted granted Critical
Publication of ES2989065T3 publication Critical patent/ES2989065T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES21813912T 2020-05-28 2021-05-28 Precursores del inhibidor de la PDE4 bioactivados de la microbiota intestinal Active ES2989065T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031023P 2020-05-28 2020-05-28
PCT/CA2021/050725 WO2021237364A1 (en) 2020-05-28 2021-05-28 Gut microbiota bioactivated pde4 inhibitor precursors

Publications (1)

Publication Number Publication Date
ES2989065T3 true ES2989065T3 (es) 2024-11-25

Family

ID=78745382

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21813912T Active ES2989065T3 (es) 2020-05-28 2021-05-28 Precursores del inhibidor de la PDE4 bioactivados de la microbiota intestinal

Country Status (9)

Country Link
US (1) US20230250123A1 (https=)
EP (1) EP4157853B1 (https=)
JP (1) JP7762168B2 (https=)
KR (1) KR20230029682A (https=)
CN (1) CN116056713B (https=)
AU (1) AU2021280418A1 (https=)
ES (1) ES2989065T3 (https=)
MX (1) MX2022014416A (https=)
WO (1) WO2021237364A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2007142929A2 (en) * 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors

Also Published As

Publication number Publication date
MX2022014416A (es) 2023-02-22
KR20230029682A (ko) 2023-03-03
JP7762168B2 (ja) 2025-10-29
JP2023528397A (ja) 2023-07-04
EP4157853B1 (en) 2024-07-31
CN116056713B (zh) 2025-09-09
US20230250123A1 (en) 2023-08-10
CN116056713A (zh) 2023-05-02
WO2021237364A1 (en) 2021-12-02
AU2021280418A1 (en) 2023-02-02
CA3174137A1 (en) 2021-12-02
EP4157853A1 (en) 2023-04-05
EP4157853A4 (en) 2023-12-13
EP4157853C0 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
US11161847B2 (en) KRAS mutant protein inhibitors
US10647711B2 (en) Azepin-2-one derivatives as RSV inhibitors
RU2667060C2 (ru) Производные маннозы для лечения бактериальных инфекций
RU2503673C2 (ru) Новое производное 5-фторурацила
US11254664B2 (en) Benzodiazepine derivatives as RSV inhibitors
EP3174879B1 (en) Substituted oxetanes and their use as inhibitors of cathepsin c
US20230357187A1 (en) Inhibitors of Dihydroceramide Desaturase For Treating Disease
US20100305120A1 (en) Compounds for treating muscular dystrophy
KR20090042239A (ko) Ｎ-(아미노헤테로아릴)-1ｈ-인돌-2-카르복스아미드 유도체,그의 제조 방법 및 치료 용도
RU2678327C2 (ru) Производные маннозы для лечения бактериальных инфекций
KR20140059164A (ko) 트라이사이클릭 자이라제 억제제
ES3051614T3 (en) Salts and prodrugs of 1-methyl-d-tryptophan
US20230108803A1 (en) Antiviral heterocyclic compounds
US20230365525A1 (en) Antiviral compounds
CN103626825B (zh) 靶向肝脏的糖原磷酸化酶抑制剂胆酸类衍生物、其制备方法及医药用途
ES2989065T3 (es) Precursores del inhibidor de la PDE4 bioactivados de la microbiota intestinal
CN112574211B (zh) 杂环类激酶抑制剂
CA3174137C (en) Gut microbiota bioactivated pde4 inhibitor precursors
WO2022092141A1 (ja) 抗ウイルス活性を有するアミド誘導体
CN116789673B (zh) 一种吡咯并嘧啶衍生物及其制备方法、药物组合物和应用
WO2006059163A1 (en) Treatment of diabetes with glycogen phosphorylase inhibitors
US11951094B2 (en) TLR2 modulator compounds, pharmaceutical compositions and uses thereof
HK40093996A (zh) 肠道微生物群生物活性pde4抑制剂前体
RU2836730C1 (ru) Амидное производное, имеющее противовирусную активность
US20250154163A1 (en) Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors